Cellceutix Corp (CTIX) 3.1600 $CTIX
Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported
Marketwired - Tue Mar 24, 7:29AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the tenth cohort in the Company's Phase 1 clinical trial of Kevetrin for advanced solid tumors being conducted at Harvard's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has been completed. Patients in the tenth cohort were treated with 450 mg/m2 of Kevetrin with no adverse events reported.
Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and Drug Administration
Marketwired - Mon Mar 16, 7:33AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to inform shareholders that further to the Company's press release on March 2, 2015, Cellceutix is this week submitting a request with the U.S. Food and Drug Administration for a pre-Investigational New Drug (IND) meeting to initiate a clinical study for one of the Company's Host Defense Proteins (HDPs) for the treatment of hidradenitis suppurativa (HS).
Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 22.52 (-0.75), EBS: 28.76 (-0.42), AMGN: 159.85 (-4.45), BMY: 64.50 (-1.26), AZN: 68.43 (-1.51), CCXI: 7.55 (+0.10), ATHX: 2.88 (+0.02), CELGZ: 2.97 (+0.16)
Cellceutix to Expand Its Skin Product Pipeline
Marketwired - Mon Mar 02, 8:32AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that it is expanding its dermatology pipeline to include novel Human Defense Protein (HDP) mimetics for the treatment of chronic skin conditions, such as acne vulgaris, rosacea, and hidradenitis suppurativa (HS). Recently conducted pre-clinical research supports these conditions as targets due to the robust antimicrobial and anti-inflammatory properties of Cellceutix's HDP mimetics. These are conditions for which there is no consistently effective treatment, as in the case of HS, or there is room to improve upon current therapies, as in acne vulgaris or rosacea. In these conditions, topical antibiotics have been used, with mixed or disappointing results, most likely due to a lack of anti-inflammatory activity in concert with an inability to treat bacteria, such as Propionibacterium acnes, that are growing increasingly resistant to current therapies. The HDP mimetics can overcome both hurdles: they have anti-inflammatory properties and they can kill key bacteria without promoting further resistance. The latter is important, because traditional antibiotics, when chronically used, are likely to promote resistance, whereas HDP mimetics, given their unique structure and mechanism of action, are unlikely to promote resistance.
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 198.62 (-2.76), ACT: 297.62 (-7.14), MDT: 77.99 (-0.43), XON: 45.37 (-0.93), CTIC: 1.81 (-0.06), PFNX: 15.94 (-0.68), JNJ: 100.60 (-0.95), ANTM: 154.41 (-2.44), NVAX: 8.27 (-0.37), SHPG: 239.29 (-2.69), ABBV: 58.54 (+0.30), TBPH: 17.35 (-0.45), SNY: 49.44 (-0.80), ALQA: 5.20 (+0.03), REGN: 451.48 (-8.30), ONCY: 0.74 (-0.03), PFE: 34.79 (-0.21), SLXP: 172.81 (+0.16), EPRS: 8.95 (+0.25), AMGN: 159.85 (-4.45), NKTR: 11.00 (-0.31), ZTS: 46.29 (-0.63), GILD: 98.13 (-2.56), ACHN: 9.86 (-0.38), GERN: 3.77 (-0.10)
IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST
PPHM: 1.35 (-0.03)
An Interview With Cellceutix CEO Leo Ehrlich
KarinCA - at Seeking Alpha - Mon Feb 09, 9:31AM CST
MRK: 57.48 (-0.86)
Cellceutix: Why An Uplisting Is Not Possible Right Now
Bleecker Street Research - at Seeking Alpha - Fri Feb 06, 1:26PM CST
$CTIX - Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon
KarinCA - at Seeking Alpha - Thu Jan 29, 3:13PM CST
JNJ: 100.60 (-0.95), CBSTZ: 0.06 (unch), ACT: 297.62 (-7.14), PFE: 34.79 (-0.21), MRK: 57.48 (-0.86), AMGN: 159.85 (-4.45), LLY: 72.65 (-1.22), ABBV: 58.54 (+0.30), NVS: 98.61 (-2.70)
Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis
Marketwired - Mon Jan 26, 6:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to announce that it is submitting a request early this week to the Food and Drug Administration (FDA) Division of Gastroenterology and Inborn Errors Products to conduct a pre-Investigational New Drug (IND) meeting to discuss development of a topical defensin-mimetic compound for the indication of induction of remission of ulcerative proctitis and ulcerative proctosigmoiditis.
Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX
Bleecker Street Research - at Seeking Alpha - Fri Jan 23, 9:30AM CST
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 62.30 (-0.22), ITCI: 23.88 (-0.85), BCLI: 4.45 (-0.04), OMER: 22.03 (-0.36), NVS: 98.61 (-2.70)
Will Cannabis Be The Biggest Thing In Biotech For 2015?
ACCESSWIRE - Thu Jan 22, 8:13AM CST
CORAL GABLES, FL / ACCESSWIRE / January 22, 2015 / Attention on marijuana stocks has increased since Colorado legalized it for recreational use in 2014. With larger institutional investment flowing into the industry, there's no doubt that this may be just the beginning for stocks in this sector. With 2016 slated as the next vote for more states to come online for legalization of medical and recreational licensing, much speculation has given rise to where to invest as it would appear not many new developments may come about until more states can come online. Biotech has been one of the identified target markets as regulation does not limit these organizations to particular state laws but more on the Federal side, specifically the FDA. From prescription sprays to cannabinoid oils, the biotech space may offer potential investment opportunity prior to the next vote.
Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Marketwired - Thu Jan 22, 6:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report that results of its recently completed phase 2b clinical trial "A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)" will be given in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015. ECCMID is one of the largest annual gatherings of infectious disease experts in the world, and an ideal forum to present the results of a clinical trial. Dr. Daniel Jorgensen, Cellceutix's Chief Medical Officer, will give the presentation during a session entitled "New Antibacterial Agents - Phase 2 and Phase 3 Clinical Trials."
Cellceutix up on report of positive results in clinical trial
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 12:11PM CST
Cellceutix Reports Spleen Lesion 'Disappears' in Patient With Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin
Marketwired - Tue Jan 20, 6:01AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report the near complete disappearance of a metastatic lesion in the spleen of a Stage 4 ovarian cancer patient who was enrolled in the Company's Phase 1 clinical trial of anti-cancer drug candidate Kevetrin(TM) being conducted at Harvard Cancer Center's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. According to information supplied by the hospital, the patient, who successfully completed three Kevetrin 3-dose cycles before discontinuing the trial, experienced increased energy, while scans showed a reduction in the amount of peritoneal fluid (ascites) during treatment with Kevetrin. Subsequent to the second and third Kevetrin cycles, scans showed the spleen lesion to be essentially undetectable and the patient's disease to be clinically stable.
Cellceutix Invites All to Attend Company's Live Webcast of Presentation at Biotech Showcase 2015 Today at 2:00 PM PT (5:00 PM ET)
Marketwired - Mon Jan 12, 6:01AM CST
Cellceutix Corporation (OTCBB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, invites all interested parties to join the Company during its live webcast presentation at Biotech Showcase 2015 today, Monday, January 12 at 2:00 PM PT (5:00 PM ET). The conference is being held at Parc 55 Wyndham San Francisco (Union Square) in San Francisco, CA on January 12-14, 2015. Cellceutix will be presenting in Room Powell.
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 9.30 (-0.04), VTAE: 11.71 (+0.40), XNCR: 15.32 (-0.13)
OTC Daily Alert Stock Watch - Cellceutix (OTC: CTIX)
WorldStockWire - Mon Dec 29, 3:15PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
New medical chief at Cellceutix
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:28AM CST
Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported
Marketwired - Tue Mar 24, 7:29AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the tenth cohort in the Company's Phase 1 clinical trial of Kevetrin for advanced solid tumors being conducted at Harvard's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has been completed. Patients in the tenth cohort were treated with 450 mg/m2 of Kevetrin with no adverse events reported. Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and Drug Administration
Marketwired - Mon Mar 16, 7:33AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to inform shareholders that further to the Company's press release on March 2, 2015, Cellceutix is this week submitting a request with the U.S. Food and Drug Administration for a pre-Investigational New Drug (IND) meeting to initiate a clinical study for one of the Company's Host Defense Proteins (HDPs) for the treatment of hidradenitis suppurativa (HS). Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 22.52 (-0.75), EBS: 28.76 (-0.42), AMGN: 159.85 (-4.45), BMY: 64.50 (-1.26), AZN: 68.43 (-1.51), CCXI: 7.55 (+0.10), ATHX: 2.88 (+0.02), CELGZ: 2.97 (+0.16)
Cellceutix to Expand Its Skin Product Pipeline
Marketwired - Mon Mar 02, 8:32AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that it is expanding its dermatology pipeline to include novel Human Defense Protein (HDP) mimetics for the treatment of chronic skin conditions, such as acne vulgaris, rosacea, and hidradenitis suppurativa (HS). Recently conducted pre-clinical research supports these conditions as targets due to the robust antimicrobial and anti-inflammatory properties of Cellceutix's HDP mimetics. These are conditions for which there is no consistently effective treatment, as in the case of HS, or there is room to improve upon current therapies, as in acne vulgaris or rosacea. In these conditions, topical antibiotics have been used, with mixed or disappointing results, most likely due to a lack of anti-inflammatory activity in concert with an inability to treat bacteria, such as Propionibacterium acnes, that are growing increasingly resistant to current therapies. The HDP mimetics can overcome both hurdles: they have anti-inflammatory properties and they can kill key bacteria without promoting further resistance. The latter is important, because traditional antibiotics, when chronically used, are likely to promote resistance, whereas HDP mimetics, given their unique structure and mechanism of action, are unlikely to promote resistance. Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 198.62 (-2.76), ACT: 297.62 (-7.14), MDT: 77.99 (-0.43), XON: 45.37 (-0.93), CTIC: 1.81 (-0.06), PFNX: 15.94 (-0.68), JNJ: 100.60 (-0.95), ANTM: 154.41 (-2.44), NVAX: 8.27 (-0.37), SHPG: 239.29 (-2.69), ABBV: 58.54 (+0.30), TBPH: 17.35 (-0.45), SNY: 49.44 (-0.80), ALQA: 5.20 (+0.03), REGN: 451.48 (-8.30), ONCY: 0.74 (-0.03), PFE: 34.79 (-0.21), SLXP: 172.81 (+0.16), EPRS: 8.95 (+0.25), AMGN: 159.85 (-4.45), NKTR: 11.00 (-0.31), ZTS: 46.29 (-0.63), GILD: 98.13 (-2.56), ACHN: 9.86 (-0.38), GERN: 3.77 (-0.10)
IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST
PPHM: 1.35 (-0.03)
An Interview With Cellceutix CEO Leo Ehrlich
KarinCA - at Seeking Alpha - Mon Feb 09, 9:31AM CST
MRK: 57.48 (-0.86)
Cellceutix: Why An Uplisting Is Not Possible Right Now
Bleecker Street Research - at Seeking Alpha - Fri Feb 06, 1:26PM CST
$CTIX - Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon
KarinCA - at Seeking Alpha - Thu Jan 29, 3:13PM CST
JNJ: 100.60 (-0.95), CBSTZ: 0.06 (unch), ACT: 297.62 (-7.14), PFE: 34.79 (-0.21), MRK: 57.48 (-0.86), AMGN: 159.85 (-4.45), LLY: 72.65 (-1.22), ABBV: 58.54 (+0.30), NVS: 98.61 (-2.70)
Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis
Marketwired - Mon Jan 26, 6:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to announce that it is submitting a request early this week to the Food and Drug Administration (FDA) Division of Gastroenterology and Inborn Errors Products to conduct a pre-Investigational New Drug (IND) meeting to discuss development of a topical defensin-mimetic compound for the indication of induction of remission of ulcerative proctitis and ulcerative proctosigmoiditis. Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX
Bleecker Street Research - at Seeking Alpha - Fri Jan 23, 9:30AM CST
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 62.30 (-0.22), ITCI: 23.88 (-0.85), BCLI: 4.45 (-0.04), OMER: 22.03 (-0.36), NVS: 98.61 (-2.70)
Will Cannabis Be The Biggest Thing In Biotech For 2015?
ACCESSWIRE - Thu Jan 22, 8:13AM CST
CORAL GABLES, FL / ACCESSWIRE / January 22, 2015 / Attention on marijuana stocks has increased since Colorado legalized it for recreational use in 2014. With larger institutional investment flowing into the industry, there's no doubt that this may be just the beginning for stocks in this sector. With 2016 slated as the next vote for more states to come online for legalization of medical and recreational licensing, much speculation has given rise to where to invest as it would appear not many new developments may come about until more states can come online. Biotech has been one of the identified target markets as regulation does not limit these organizations to particular state laws but more on the Federal side, specifically the FDA. From prescription sprays to cannabinoid oils, the biotech space may offer potential investment opportunity prior to the next vote.
Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Marketwired - Thu Jan 22, 6:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report that results of its recently completed phase 2b clinical trial "A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)" will be given in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015. ECCMID is one of the largest annual gatherings of infectious disease experts in the world, and an ideal forum to present the results of a clinical trial. Dr. Daniel Jorgensen, Cellceutix's Chief Medical Officer, will give the presentation during a session entitled "New Antibacterial Agents - Phase 2 and Phase 3 Clinical Trials." Cellceutix up on report of positive results in clinical trial
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 12:11PM CST
Cellceutix Reports Spleen Lesion 'Disappears' in Patient With Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin
Marketwired - Tue Jan 20, 6:01AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report the near complete disappearance of a metastatic lesion in the spleen of a Stage 4 ovarian cancer patient who was enrolled in the Company's Phase 1 clinical trial of anti-cancer drug candidate Kevetrin(TM) being conducted at Harvard Cancer Center's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. According to information supplied by the hospital, the patient, who successfully completed three Kevetrin 3-dose cycles before discontinuing the trial, experienced increased energy, while scans showed a reduction in the amount of peritoneal fluid (ascites) during treatment with Kevetrin. Subsequent to the second and third Kevetrin cycles, scans showed the spleen lesion to be essentially undetectable and the patient's disease to be clinically stable. Cellceutix Invites All to Attend Company's Live Webcast of Presentation at Biotech Showcase 2015 Today at 2:00 PM PT (5:00 PM ET)
Marketwired - Mon Jan 12, 6:01AM CST
Cellceutix Corporation (OTCBB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, invites all interested parties to join the Company during its live webcast presentation at Biotech Showcase 2015 today, Monday, January 12 at 2:00 PM PT (5:00 PM ET). The conference is being held at Parc 55 Wyndham San Francisco (Union Square) in San Francisco, CA on January 12-14, 2015. Cellceutix will be presenting in Room Powell. Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 9.30 (-0.04), VTAE: 11.71 (+0.40), XNCR: 15.32 (-0.13)
OTC Daily Alert Stock Watch - Cellceutix (OTC: CTIX)
WorldStockWire - Mon Dec 29, 3:15PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
New medical chief at Cellceutix
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:28AM CST
